$REGN
AI AnalysisGenerated on May 11, 2026
AI Score
Buy$REGN
Regeneron Pharmaceuticals
$REGNNASDAQHealthcareLarge-Cap
Regeneron discovers, develops, and commercializes medicines for serious diseases including Dupixent and Eylea.
Market Cap
$115.0B
Revenue (TTM)
$13.8B
+6.0%
Net Income (TTM)
$4.4B
+8.0%
EPS (TTM)
$40.00
P/E Ratio
28.0
Dividend Yield
0.0%
52-Week Range
$750-$1050
Beta
0.32
Dimension Scores
Fundamental
80Technical
72Sentiment
76Risk / Reward
78Momentum
72Financial Health
Profitability
85strong
Growth
75strong
Liquidity
86strong
Solvency
82strong
Efficiency
78strong
Valuation, technical analysis, investment thesis, risk assessment and more for $REGN
Free · No credit card required
Disclaimer: AI-generated analysis for educational purposes only. Not financial advice. Always consult a qualified financial advisor.